1. Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study
- Author
-
Peng‐Xiang Wang, Yun‐Fan Sun, Wei‐Xiang Jin, Jian‐Wen Cheng, Hai‐Xiang Peng, Yang Xu, Kai‐Qian Zhou, Li‐Meng Chen, Kai Huang, Sui‐Yi Wu, Bo Hu, Ze‐Fan Zhang, Wei Guo, Ya Cao, Jian Zhou, Jia Fan, and Xin‐Rong Yang
- Subjects
circulating tumor cell ,enumeration ,integrated platform ,liquid biopsy ,machine learning‐based image recognition ,single‐cell sequencing ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX®‐i120 platform to facilitate negative enrichment, immunofluorescent labeling, and machine learning‐based identification of CTCs. Analytical performances were evaluated, and a total of 477 participants were enrolled to validate the clinical feasibility of ChimeraX®‐i120 CTC detection. We analyzed copy number alteration profiles of isolated single cells. The ChimeraX®‐i120 platform had high sensitivity, accuracy, and reproducibility for CTC detection. In clinical samples, an average value of > 60% CTC‐positive rate was found for five cancer types (i.e., liver, biliary duct, breast, colorectal, and lung), while CTCs were rarely identified in blood from healthy donors. In hepatocellular carcinoma patients treated with curative resection, CTC status was significantly associated with tumor characteristics, prognosis, and treatment response (all P
- Published
- 2021
- Full Text
- View/download PDF